The aftermath of the Allergan divestiture and acquisition event is currently being digested by Wall Street, because the repercussions are likely to be larger than just the single day news. The move by Allergan is a transformative shift and an RBC Capital Markets research note looks at what could become a major trend. What could surprise institutional investors, the analysis notes, is the size of the acquisition spree. RBC: “Investors legitimately believe that the Allergan deal… is a sign that it is theoretically possible that large-cap biotech companies” are now in play What was interesting about the July 28 note was that…
Allergan Acquisition Spree? Some Potential Big Targets
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.